LACTOLOGY FOUNDATION

Antihistamines in ATC class A04AB are first‑generation H1‑antagonists used as antiemetics for motion sickness and vertigo, with sedative and anticholinergic properties that require caution in pregnant and breastfeeding patients.medpedia.framar+2

ATC class and members

ATC A04AB comprises antihistamines used primarily as antiemetics and antivertigo agents, distinct from systemic antiallergic antihistamines in other ATC groups.medcentral+1
Main single‑agent entries include dimenhydrinate (A04AB02), thiethylperazine (A04AB03), meclozine/meclizine (A04AB04) and diphenhydramine (A04AB05), as well as several fixed‑dose combinations containing dimenhydrinate, meclozine, diphenhydramine, doxylamine, chlorphenoxamine and promethazine.drugbank+2

Mechanism of action

These agents act predominantly as H1‑receptor antagonists in the central nervous system and vestibular apparatus, blocking histamine‑mediated signalling involved in nausea, vomiting and vertigo.webmd+2
Most compounds (e.g. dimenhydrinate, meclozine, diphenhydramine, promethazine) also have anticholinergic and sedative effects, further dampening vestibular input and the vomiting reflex.pediatriconcall+2

Clinical indications

A04AB antihistamines are used for prevention and treatment of motion sickness‑related nausea, vomiting and dizziness, and for symptomatic relief in labyrinthine disorders such as Ménière disease.medlineplus+2
Some members (e.g. promethazine, diphenhydramine‑containing combinations) are also used for postoperative nausea and vomiting, drug‑induced emesis, and occasionally as adjuncts in pregnancy‑related nausea and vomiting.babyyourbaby+2

General adverse effects

Class‑typical adverse effects include drowsiness, dizziness, dry mouth, nausea, blurred vision, urinary retention and constipation, reflecting central sedation and anticholinergic activity.medpedia.framar+2
At higher doses or in susceptible individuals, confusion, paradoxical CNS stimulation (especially in children), tachycardia, glaucoma exacerbation and, rarely, haemolytic anaemia have been reported for some agents.medcentral+2

Contraindications and cautions

These antihistamines are contraindicated in patients with known hypersensitivity to the active substance or excipients.pediatriconcall+1
They should be used with caution in glaucoma, prostatic hypertrophy, urinary bladder outflow obstruction, cardiovascular disease including hypertension, thyroid dysfunction, hepatic or renal impairment, seizure disorders and chronic lung disease.medpedia.framar+2

Dimenhydrinate (A04AB02, A04AB52)

Dimenhydrinate is a first‑generation antihistamine (salt of diphenhydramine and 8‑chlorotheophylline) indicated for prevention and treatment of nausea, vomiting and vertigo associated with motion sickness and other vestibular disorders.wikipedia+2
It is commonly given orally 30 minutes to 1 hour before travel, with adult doses typically 50–100 mg every 4–6 hours as needed, not exceeding 400 mg per day.reference.medscape+2

Meclozine / Meclizine (A04AB04, A04AB54)

Meclozine (meclizine) is a long‑acting H1‑antagonist used for motion sickness and vertigo, often considered more effective or better tolerated than dimenhydrinate in some settings.sciencedirect+1
Large cohort data involving over 16,000 pregnancies exposed in the first trimester found no increase in major malformations or adverse delivery outcomes, supporting its use in pregnancy when clinically indicated.pubmed.ncbi.nlm.nih+1

Diphenhydramine and other agents (A04AB05, combinations)

Diphenhydramine‑containing products in A04AB are used as antiemetics in motion sickness and postoperative settings, leveraging strong H1‑blocking and sedative effects.babyyourbaby+1
Promethazine, doxylamine and chlorphenoxamine combinations extend the antiemetic spectrum but share similar sedating and anticholinergic toxicity profiles.womensmentalhealth+2

Toxicological profile

From a toxicological standpoint, A04AB antihistamines have relatively wide therapeutic margins in adults, but central sedation, anticholinergic burden and potential cardiac effects (e.g. tachyarrhythmias) are key safety concerns.medcentral+2
Overdose can lead to pronounced CNS depression or paradoxical agitation, anticholinergic toxidrome and, in severe cases, seizures or arrhythmias; management is supportive with close monitoring of vital functions.pediatriconcall+1

Use in pregnancy

Available human data suggest that dimenhydrinate, meclozine/meclizine and diphenhydramine do not increase the overall risk of major congenital malformations when used at standard doses in pregnancy.mothertobaby+2
Promethazine is likewise not associated with an increased rate of birth defects, although high doses near term may delay lactogenesis.sps+1

Lactation‑specific safety

Evidence on transfer of individual A04AB antihistamines into human breast milk and on direct infant outcomes is limited, with most data being extrapolated from pharmacology and small clinical observations.womensmentalhealth+1
Sedating first‑generation antihistamines may transiently reduce serum prolactin and potentially affect milk production, especially in the early postpartum period, while also posing a risk of infant sedation and feeding difficulties if significant amounts reach the infant.sps+1

Lactological risk assessment

For dimenhydrinate, meclozine/meclizine, diphenhydramine and promethazine used as antiemetics, short‑term, occasional use at standard doses in a healthy breastfeeding mother is unlikely to produce serious toxicity in a full‑term infant, but careful monitoring for infant sedation, poor suckling or feeding difficulties is advisable.mothertobaby+2
Given the limited milk‑specific data and potential impact on early lactation, these agents are best categorised as “use with caution during breastfeeding; prefer non‑sedating antihistamines or non‑antihistamine antiemetics when feasible, and avoid high or repeated doses in the early postpartum period.”womensmentalhealth+1

Practical breastfeeding management

When an A04AB antihistamine is required in a breastfeeding patient, clinicians should: minimise dose and duration, schedule dosing after feeds to reduce peak milk concentrations at the next feed, and observe the infant for excessive sleepiness, hypotonia or feeding problems.sps+1
In mothers of preterm or medically fragile infants, or when prolonged high‑dose therapy is anticipated, temporary interruption of breastfeeding with maintenance of milk expression and consideration of alternative antiemetics or non‑sedating antihistamines (e.g. cetirizine, loratadine) is prudent.womensmentalhealth+1